FK614 - 10mM in DMSO , Peroxisome proliferator-activated receptor gamma modulator, CAS No.193012-35-0, Peroxisome proliferator-activated receptor gamma modulator

CAS: 193012-35-0 Cat. No.: F656584 Formula: C₂₁H₂₃Cl₂N₃O₃S Peso molecolare: 468.40 PubChem CID: 9869229

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Panoramica

FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes

In Vitro

FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia. FK614 is a non-TZD insulin sensitizer. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level. FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: db/db Mice Dosage: 0.1~10 mg/kg Administration: P.o. Result: Improved the impaired glucose tolerance. Animal Model: db/db Mice Dosage: 0.32~3.2 mg/kg Administration: P.o. Result: Dose-dependently reduced plasma glucose level.

IC50& Target:PPAR-γ

Specifications

Specifiche e purezza

10mM in DMSO

Meccanismi biochimici e fisiologici

FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adi

Condizioni di conservazione di stoccaggio

Store at -80°C

Spedito in

Dry ice packs + Cold packs

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Tipo di azione

MODULATOR

Meccanismo d'azione

Peroxisome proliferator-activated receptor gamma modulator

Proprietà del prodotto

• ALogP: 5.3

Nomi e identificatori

• Isomeri SMILES: CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C
• CAS alternativo: 193012-35-0
• PubChem CID: 9869229
• Termini MeSH: 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3 H-benzimidazole-5-carboxamide;FK614 cpd
• Peso molecolare: 468.40